International Stem Cell Corporation to Present Results of Neural Stem Cell Transplantation for …

CARLSBAD, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) — International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today announced that it will present data on the company’s first-in-human clinical study in Parkinson’s disease at Neuroscience 2016. Session Information Type: NanosymposiumTitle: Transplants and Other Treatments of Parkinson’s DiseaseDate: November 14, 2016Time: 8:00 AM Location: SDCC 1B, San Diego Convention Center About the clinical studyThe Phase I clinical study is a dose escalation safety and preliminary efficacy study of ISC-hpNSC®, intracranialy transplanted into patients with moderate to severe Parkinson’s disease (ClinicalTrials.gov Identifier: NCT02452723). The open-label, single center, uncontrolled clinical trial will evaluate three different dose regimens of 30,000,000 to 70,000,000 neural cells. A total of 12 participants with moderate to severe Parkinson’s disease…


Link to Full Article: International Stem Cell Corporation to Present Results of Neural Stem Cell Transplantation for …

Pin It on Pinterest

Share This